COMMENTS TO AUTHORS
There is no doubt that in humans NDDs and type 2 DM are linked because of the effects of insulin lack.
Therefore, the topic is of high interest and worth considering. The limited space and references number at disposal of the author are undoubtedly serious constraints which can limit or offuscate the clarity of the text. i would like to give to the author just a few suggestions to strengthen the editorial.
1. Drug repurposing is fine as discussed in the text, but has the advantage to make known collateral effects of the considered drugs when given to humans, which are mostly shared by the two kinds of drugs (pancreatitis, gastrointestinal symptoms, flu-like symptoms, skin rashes, dyspnea, severe joint pain, etc.). Moreover, no mention is made of the work of Rathmann and, Kostev K. J Diabetes Complications. 2017 Apr;31(4):687-692 concerning the association of dipeptidyl peptidase 4 inhibitors with risk of metastases in patients with type 2 diabetes and breast, prostate or digestive system cancer.
Such risks should be mentioned and discussed in relation to the possibility that intranasal administration route might attenuate such unwanted collateral effects, which should be demonstrated. 2. The ability or inability of Linagliptin to cross the BBB should be clarified at a single point in the text.
3. Considering an induced BBB dysfunction a "blessing" is an unacceptable proposition given the several harmful alterations it can induce in the brain including the accumulation of iron ions considered by some authors as one of the driving factors of Alzheimer's disease.
4. Take heed please that no effective drug against Alzheimer's disease has hitherto been approved and shown to be beneficial.
5. Neuroprotective effects in animal models have hitherto failed to translate in human Alzheimer patients: a word of caution should be in order here.
6. The fact that the same drugs could be beneficial for a wide spectrum of NDDs in certainly of interest though indicating a potentially symptomatic or generic mechanism of action. As a matter of fact, NDDs are known to have rather different pathogenetic mechanisms and the relation of these different mechanisms to the two group of drugs considered should be elaborated.
